


## (S)-Ceralasertib

<b>Cat. No.:</b>	HY-19323A		
<b>CAS No.:</b>	1352226-87-9		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>24</sub> N <sub>6</sub> O <sub>2</sub> S		
<b>Molecular Weight:</b>	412.51		
<b>Target:</b>	ATM/ATR		
<b>Pathway:</b>	Cell Cycle/DNA Damage; PI3K/Akt/mTOR		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (242.42 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4242 mL	12.1209 mL	24.2418 mL
	5 mM	0.4848 mL	2.4242 mL	4.8484 mL
	10 mM	0.2424 mL	1.2121 mL	2.4242 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC<sub>50</sub> of 2.578 nM<sup>[1]</sup>. (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition<sup>[2]</sup>.

### CUSTOMER VALIDATION

- 
- Research Square Preprint. 2023 May 31.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215.

[2]. Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA